EUCTR2007-003340-30-IT进行中（未招募）不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial) - AGENDA
Genta Incorporated0 个研究点目标入组 300 人开始时间: 2008年2月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The following criteria must be met before registration not more than 15 days prior to randomisation: 1. Histologically confirmed diagnosis of melanoma 2. Progressive disease that is not surgically resectable, or metastatic Stage IV disease 3. LDH /= 20 mm with conventional techniques and >/= 10 mm with spiral CT, based on Response Evaluation Criteria in Solid Tumors (RECIST) Lesions that are considered nonmeasurable include: Bone lesions, Ascites and pleural/pericardial effusions; Lymphangitis cutis/pulmonis ; Abdominal masses not confirmed and not followed by imaging studies; Cystic lesions; Tumors treated by irradiation or intra-tumor injection therapy without progression in that area or measurable disease outside that area 6. ECOG performance status /= 1500/mm3 b. Platelet count >/= 100,000/mm3 c. Hemoglobin >/= 11 g/dL without need for hematopoietic growth factor or transfusion support d. Serum creatinine /= 50 mL/min e. Serum bilirubin /= 3.0 g/dL j. Prothrombin time (PT) Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior cytotoxic chemotherapy, including regional perfusion, or prior Genasense treatment 2. Need for other anticancer treatment (such as chemotherapy, radiation, or biologic or investigational therapies) while receiving protocol therapy in this study 3. Primary ocular or mucosal melanoma 4. Bone-only metastatic disease 5. History or presence of brain metastasis or leptomeningeal disease 6. History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 or more years) 7. Significant medical disease other than cancer, such as: uncontrolled congestive heart failure; active symptoms of coronary artery disease (defined as uncontrolled arrhythmias or recurrent chest pain despite prophylactic medication); New York Heart Association Class III or IV disease; cardiovascular signs and symptoms >/= Grade 2 by common toxicity criteria (CTC) during the 4-week period prior to initiation of protocol therapy; uncontrolled seizure disorder; history of chronic hepatitis or cirrhosis; active infection; uncontrolled diabetes mellitus; requirement for chronic corticosteroid treatment with an average dose >/= 20 mg/day of prednisone (or equivalent); requirement for concurrent immunosuppressive drug(s); active autoimmune disease 8. Organ allograft 9. Known human immunodeficiency virus infection 10. Pregnancy or lactation;
- •- Women of childbearing potential and sexually active males must be advised to take precautions to prevent pregnancy during protocol therapy.
- •- All subjects must use an effective form of birth control during protocol therapy (except if the women is post menopause for > 1 year or surgically sterile). 11. Known hypersensitivity to dacarbazine or phosphorothioate-containing oligonucleotides 12. Use of any experimental therapy within 3 weeks prior to screening evaluations 13. Need for concomitant anticoagulant therapy with the exception of 1 mg/day of warfarin for central-line prophylaxis
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)Advanced Melanoma.MedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2007-003340-30-FRGenta Incorporated300
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)Advanced melanomaEUCTR2007-003340-30-DEGenta Incorporated300
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)Estudio multicéntrico, aleatorizado y doble ciego de dacarbazina con o sin Genasense® en pacientes con melanoma avanzado y niveles bajos de LDH que no han recibido tratamiento previo con quimioterapia (Ensayo AGENDA)Advanced Melanoma.Melanoma AvanzadoMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2007-003340-30-ESGenta Incorporated300
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial) - The AGENDA TrialAdvanced Melanoma.MedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2007-003340-30-CZGenta Incorporated300
进行中（未招募）
1 期
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)EUCTR2007-003340-30-GBGenta Incorporated300